Are you Dr. Wegener?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 28 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
22 Stanfield Ave
Broomall, PA 19008Phone+1 610-353-4738- Is this information wrong?
Summary
- Dr. William Wegener, MD is a board certified nuclear medicine physician in Broomall, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania and New Jersey.
Education & Training
Drexel University College of Medicine/Hahnemann University HospitalResidency, Radiology-Diagnostic, 1990 - 1991
University of Pennsylvania Health SystemResidency, Nuclear Medicine, 1988 - 1990- Drexel University College of Medicine/Hahnemann University HospitalInternship, Internal Medicine, 1987 - 1988
University of Miami Leonard M. Miller School of MedicineClass of 1987
Certifications & Licensure
PA State Medical License 1990 - 2024
NJ State Medical License 2002 - 2019- American Board of Nuclear Medicine Nuclear Medicine
Clinical Trials
- Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Start of enrollment: 1997 Mar 01
- Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Start of enrollment: 1997 Mar 01
- Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Start of enrollment: 2000 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 81 citationsSacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trialKevin Kalinsky, Jennifer R. Diamond, Linda T. Vahdat, Sara M. Tolaney, Dejan Juric, Joyce O'Shaughnessy, RL Moroose, Ingrid A. Mayer, Vandana G. Abramson, David M. Gol...> ;Annals of Oncology. 2020 Dec 1
- 437 citationsSacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff, Jennifer R. Diamond, Joyce O'Shaughnessy, Rebecca L. Moroose, Alessandro D. Santin...> ;The New England Journal of Medicine. 2019 Feb 20
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients with Metastatic Triple-Negative Breast CancerAditya Bardia, William A Wegener, Ingrid A Mayer, Vandana Abramson, Jordan Berlin, Dejan Juric, Sara M Tolaney, Allyson J Ocean, Steven J Isakoff> ;Journal of Clinical Oncology.
- Join now to see all
